Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Persistence at No Cost: A Clinic Program Where Patients Paid Nothing

With the drug free to patients, median persistence was 10.7 months across 2,306 people, and 23% reached the 2.4 mg trial dose.

Editorial profile: Neil SandersBuy This GLP Editorial Team5 min read
Semaglutide users, dose reachedreached ≥1 mg81%reached 2.4 mg23%Median persistence 10.7 months — at no cost to the patient

A program with no price

A multidisciplinary obesity clinic at an academic medical center ran a Medical Weight Loss Bundle at no cost to the patient, and looked back at everyone aged 18 to 75 who enrolled between January 2022 and December 2024. [1] Of 2,855 enrollees, 2,306 — 81% — filled at least one GLP-1 prescription. Median age was 46, and 85% were women. Persistence was defined mechanically: continuous fills with no gap of 84 days or more.

Median persistence was 10.7 months, with an interquartile range of 5.4 to 16.3 months. The study measured prescription refills in a single clinic program [1].

Studies of how long people stay on a GLP-1 measure whether participants continued treatment. They cannot predict who will use every fill in a prepaid plan. In this study, people still stopped when the medication was free.

Where the dose stopped

Titration is the other half. Of semaglutide users, 81% escalated to at least 1 mg — but only 23% ever reached 2.4 mg, the dose the weight-loss trials ran at. Of the small tirzepatide group, 75% reached 10 mg or more and 28% reached 15 mg.

Participants in this program received medication without paying for it. A separate Danish study of semaglutide maintenance doses tracked doses and interruptions in one general practice. The studies describe different settings. For a price comparison, use the dose your prescriber recommends and ask how the provider bills if it changes.

Tirzepatide was the sole agent for only 117 people here, about 5% of the cohort. Its titration numbers come from a small group and should be read that way.

The weight figures have a condition attached

Among patients persistent for at least six months, median weight loss was 9.4%, IQR 6.0 to 13.4. Among those persistent for at least twelve, it was 14.4%, IQR 9.5 to 20.5. These estimates apply to those groups of continuing patients [1].

The year-one weight results describe patients who remained on treatment for at least a year. The study did not report the same outcome for everyone who started.

What to do with it before buying

If you are considering an annual offer, use the plan term checker to see which published prices require prepayment. Compare the total due and check whether the provider refunds unused treatment if you stop early.

The median published monthly price for injectable semaglutide in our catalog was $186 as of November 2026. The survey of why patients stopped treatment covers reported costs and side effects. The clinic study does not tell us how long people who pay for medication will stay on it.

Frequently asked

If the drug was free, why did people stop?
The study measured how long patients continued filling prescriptions. It did not establish why they stopped or compare the no-cost program with a paid program.
Is 14.4% weight loss what I should expect?
The 14.4% figure is the median among patients who stayed on treatment for at least 12 months. Individual results vary.
Why did so few reach 2.4 mg?
The study reports the ceiling rather than the reason — 81% got to 1 mg and 23% to 2.4 mg. The study did not establish why individual patients stayed at a lower dose.
Does this apply to buying from a website?
The study followed one no-cost program at an academic clinic. It did not measure how long people stayed on treatment with online providers.

Sources

  1. [1] Samuels JM, et al. (2025). Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic Diabetes, Obesity and Metabolism. PMID 40762026

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence